Stanley Erck is the President and CEO of Novavax, Inc. biotechnology company.
Stanley is a proficient CEO in the biotechnology enterprise. He has originated multiple products from early start-up through Phase2/3 clinical trials in infectious disease, vaccines.
The CEO specializes in autoimmune disease, infectious disease, immunology, and genetic disease.
Novavax is a biotechnology company that facilitates enhanced health globally by discovering and developing innovative vaccines.
Who Is Stanley Erck? Wikipedia and Biography Of Novavax CEO
Stanley Erck is the CEO of an American biotech company, Novavax, developing vaccines to counter various contagious diseases.
Although a famous figure, Stanley Erck does not have his biography on Wikipedia at the moment. Erck is also the president and Director of the Novavax Company for about 12 years now.
Novavax is based in Gaithersburg, Maryland that has developed experimental vaccines for Ebola, influenza, and further emerging infectious diseases. Currently, they are working on their COVID-19 vaccine.
He is also a member of the board of directors at BioCryst Pharmaceuticals. It has already been more than 13 years since he first started working here in 2008.
The President, Erck did his MBA in Economics and Finance from The University of Chicago Booth School of Business in 1976.
He has also worked as CEO for different companies like PHT Corporation, Lomai Corporation, and as Vice President in Procept and Genzyme Genetics.
Stanley Erck Age Revealed
Stanley Erck is currently 72 years old as per Wallmine, and it has already been more than a decade that Erck has been working in Novavax Inc.
The CEO of this company has been maintaining this position for the last 12 years.
There are one oldest and twelve younger executives at Novavax. Not to mention Micheal McManus is the oldest executive at Novavax, Inc.
Although a quick online search shows nothing, his bio can be read on his LinkedIn account.
Stanley Erck Salary & Net Worth Revealed
Stanley Erck estimated salary is around $600 thousand annually. The estimated net worth is at least over $11 million dollars as of 2021.
However, the mentioned digit is just an assumption. Erck possesses over 6,967 units of Novavax stock worth over $5,760,799.
Over the last 13 years, the CEO has sold NVAX stock value over $3,553,000. Furthermore, he makes $2,438,560 as Chief Executive Officer, President, and Director at Novavax.